New York, June 5, 2026, 11:06 (EDT)
- Ironwood shares moved up 0.9% to $3.43 in early trading Friday. The iShares Nasdaq Biotechnology ETF was off 0.3%.
- Management was at the Jefferies Global Healthcare Conference on Thursday.
- Ironwood’s next near-term marker is the June 15 maturity of its 1.50% convertible notes.
Ironwood Pharmaceuticals stock was up 0.9% at $3.43 in Friday morning trading, putting the company’s market cap around $572 million. Investors turned more attention to the bowel-disorder drugmaker after management took part in a Jefferies healthcare event and with a key debt maturity approaching in mid-June.
Ironwood’s 2026 outlook hinges less on daily share prices and more on LINZESS cash flow covering debt and paying for another trial. The Boston drugmaker’s execs appeared at a Jefferies Global Healthcare Conference fireside chat on June 4, the last scheduled investor event before its notes come due.
Ironwood said last month that U.S. net sales of LINZESS jumped 97% in the first quarter to $272.5 million, driven by stronger net pricing and a 5% rise in prescription demand. Total revenue was $106.5 million. Net income on a GAAP basis came in at $40.8 million. Adjusted EBITDA, which leaves out interest, tax, depreciation and amortization, was $76.7 million.
Chief Executive Tom McCourt said better net pricing and mid-single-digit LINZESS prescription gains drove the quarter. He said strong revenue in the first quarter should put the company in a good spot to pay off its 2026 convertible notes in June.
Convertible notes are a type of debt that can turn into shares. Ironwood’s 1.50% convertible senior notes are due to mature June 15, 2026, unless the company converts or buys them back sooner, according to a regulatory filing.
Ironwood finished March with $220.5 million in cash and cash equivalents. The company had $385.0 million drawn on its revolving credit facility at the end of the first quarter, according to its results release.
Ironwood kept its 2026 outlook, sticking with targets for LINZESS U.S. net sales of $1.125 billion to $1.175 billion, total revenue of $450 million to $475 million and adjusted EBITDA above $300 million. Those numbers still lean on LINZESS, the company’s main constipation and IBS drug, sold in the U.S. with AbbVie.
LINZESS picked up an updated label last week. Ironwood said the FDA has signed off on the drug for kids 2 and up with functional constipation, expanding it from the earlier 6-and-older age group.
Competition in this space is active. Ardelyx is selling IBSRELA for adults with IBS-C. Bausch Health’s Trulance is also on the market, approved in adults for both IBS-C and chronic idiopathic constipation, where the cause is not known.
Ardelyx ended up 2.6% in Friday trading, with Bausch Health up 1.3% and AbbVie, Ironwood’s LINZESS partner, tacking on 1.4%. The iShares Nasdaq Biotechnology ETF shed 0.3%. Ironwood made a small gain, standing out but not by much in the group.
Ironwood is looking past LINZESS. Chief Medical Officer Michael Shetzline said last month the company is still set to start the STARS-2 study, a Phase 3 trial testing apraglutide for short bowel syndrome with intestinal failure. Phase 3 trials usually test for efficacy and safety before a company files for approval.
Ironwood’s filing laid out the risk. The company said it can’t guarantee enough liquidity to cover debt as it matures, and AbbVie collaboration revenue will keep making up a big part of overall revenue for now. If LINZESS demand, pricing, debt payments or apraglutide enrollment slip, there’s less margin for error.
